Global Axial Spondyloarthritis Market is Expected to Grow at Significant CAGR 13.44 During the Forecast Period, 2022-2032

 The ankylosing spondylitis and other members of the spondyloarthritis (SpA) family were considered variations of rheumatoid arthritis (RA) up until the early 1960s. As a result, SpA and RA were initially considered to be separate illnesses, but soon after they were found to be inter-connected due to clinical, laboratory, and imaging features. For the last two decades, axial spondyloarthritis (axSpA) has been the subject of major advances in understanding the disease. Additionally, over the years, the distinction between axial and peripheral SpA as well as the connections between non-radiographic and radiographic axSpA has been formalized. In 2009, the term "axial spondyloarthritis" was introduced to describe a diverse disease family that shares clinical and genetic features, such as involvement of the axial skeleton. The following figure shows the evolution of axSpA over the years. The landscape of axial spondyloarthritis is massively growing, with many emerging and legacy companies venturing into the industry with their respective therapeutic portfolio exclusively developed and designed for the treatment of axial spondyloarthritis (axSpA) such as ankylosing spondylitis and non-radiographic axial spondyloarthritis. Additionally, axSpA is associated with several co-morbidities and extra-articular manifestations such as cardiovascular risk, inflammatory bowel disease, and uveitis. Through imaging, genetic, and biomarker studies, researchers are gaining deeper understanding of the biology of axSpA, which will likely resolve many current problems in axSpA diagnosis and classification. Though there is no cure for axSpA, but there are emerging therapies in the global axial spondylopathies market that improves the symptoms, signs, and quality of life in patients with axSpA.

The current study aims to assess the global axial spondyloarthritis market by focusing on the marketed and potential pipeline therapies catering to ankylosing spondylitis and non-radiographic axial spondyloarthritis. The current market for axial spondyloarthritis is majorly dominated by the pharmaceutical companies such as AbbVie Inc., Amgen Inc., Pfizer Inc., Johnson & Johnson Services, Inc., and Novartis International AG.

The global axial spondyloarthritis market is expected to witness high growth, attributing to the growing prevalence of axial spondyloarthritis, favorable regulatory environment, and increase in adoption of biological agents in the field of axial spondyloarthritis. The continued significant investments by the emerging and legacy companies to meet industry demand and the growing adoption of novel therapeutics by the rheumatologists are the major factors propelling the growth of the global axial spondyloarthritis market.

The preceding figure represents the global axial spondyloarthritis market from 2021 to 2032. The market size in 2021 was $1,873.8 million and is expected to reach $7,954.9 million in 2032, growing at a CAGR of 13.44% during the forecast period, 2022-2032.